Removing this variability allows constant improvement through ongoing outcomes analysis and optimisation of the 'A constant' or its equivalent in IOL power calculation formulae.
46 The HOPE/TOO (The ongoing Outcomes) study found decreased development of diabetes in the follow-up phase, suggesting an added benefit of long-term ramipril.
The latter was also a major limitation in several large clinical trials, for example, the Heart Outcomes Prevention Evaluation (HOPE) (137, 158) and the HOPE-The Ongoing Outcomes (17).
Nevertheless, while ongoing outcome studies with aliskiren in patients with heart failure and diabetic kidney disease are on their way to completion, this study does not provide evidence for the use of aliskiren as an add-on post-myocardial infarction.
In this review, we outline those CV risk factors that this class appears to influence and provide the design features and trial characteristics of six ongoing outcome trials involving more than 41,000 individuals with T2DM.
For the purposes of this study we used the Psoriatic Arthritis Magnetic Resonance Imaging Scoring system (PsAMRIS) currently being developed and validated by an ongoing Outcome Measures in Rheumatology Clinical Trials (OMERACT -based prOMERACT -based
While anticipating the results of the ongoing outcome trials, several analyses with pooled data from shorter term trials have been conducted to explore the CV safety profiles of the SGLT-2 inhibitors.
Because of the possibility that publication of these trials was delayed owing to ongoing outcome assessments, we performed a planned subgroup analysis involving trials in which the recruitment status was listed as "completed".
20 Information on cancer histological subtypes was also collected for a subset of the cases through cancer registries or reviews of hospital medical notes as part of the ongoing outcome adjudication for major diseases.
The aims of this audit were as follows: to monitor the real-life use of DrotAA and subsequent outcomes; to undertake a rigorous, nonrandomized evaluation of the effectiveness of DrotAA, by linking the data on DrotAA to the ongoing outcome audit for all admissions to adult, general critical care units; and to compare our results with those from the PROWESS study.
This review provides an overview on the potential for SGLT-2 inhibitors to reduce CV risk beyond glucose-lowering effects and presents an overview of the similarities and differences of the currently six ongoing outcome trials from this class, currently involving more than 41,000 patients.
